The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma.
 
Stefania Maraka
No Relationships to Disclose
 
Morris D. Groves
Employment - Texas Oncology
Consulting or Advisory Role - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Aaron Gerald Mammoser
No Relationships to Disclose
 
Isaac Melguizo-Gavilanes
No Relationships to Disclose
 
Charles A. Conrad
No Relationships to Disclose
 
Ivo Tremont-Lukats
Honoraria - Optune
Travel, Accommodations, Expenses - Optune
 
Monica Elena Loghin
No Relationships to Disclose
 
Barbara Jane O'Brien
Honoraria - Monteris Medical
Consulting or Advisory Role - Abbvie
Travel, Accommodations, Expenses - Kadmon
 
Vinay K. Puduvalli
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - DePuy Companies; Foundation Medicine; Nektar; Orbus Therapeutics
Consulting or Advisory Role - Nektar; Novocure; Threshold Pharmaceuticals
Research Funding - DNAtrix; Genentech; Plexxikon
 
Erik P. Sulman
Honoraria - Merck Sharp & Dohme; Novocure
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Abbvie (Inst); Novocure (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Novocure
 
Kenneth R. Hess
No Relationships to Disclose
 
Kenneth D. Aldape
Consulting or Advisory Role - Celldex
Speakers' Bureau - Merck
Travel, Accommodations, Expenses - Merck
 
Mark R. Gilbert
Honoraria - Abbvie; Cell Medica; Genentech/Roche; HERON; Merck; Wellcome Trust
 
John Frederick De Groot
Employment - Helsinn Therapeutics (I); ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; AstraZeneca; Boston Biomedical; CarThera; Celldex; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Merck; Novogen; Omniox; Oxigene; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support
 
W. K. Alfred Yung
Honoraria - Amgen; DNAtrix
Consulting or Advisory Role - Amgen; DNAtrix
 
Marta Penas-Prado
Consulting or Advisory Role - AGIOS; Lilly
Research Funding - Abbvie (Inst); Agios (Inst); AROG (Inst); DelMar Pharmaceuticals (Inst); DNAtrix (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Novartis (Inst); Orbus Therapeutics (Inst)